ASX:EMDPharmaceuticals, Biotechnology & Life SciencesPharmaceuticals
Emyria Ltd
$0.047
Day Range
$0.047 – $0.048
52 Week Range
$0.036 – $0.078
Volume
267.74K
Avg Volume (10D)
500.11K
Market Cap
$37.91M
Price Chart
Market Statistics
Open$0.048
Previous Close$0.047
Day High$0.048
Day Low$0.047
52 Week High$0.078
52 Week Low$0.036
Valuation
Market Cap37.91M
Shares Outstanding806.56M
Price to Book3.12
Trading Activity
Volume267.74K
Value Traded12.60K
Bid$0.046 × 120,265
Ask$0.047 × 69,484
Performance
1 Day0.00%
5 Day6.82%
13 Week-6.00%
52 Week-4.08%
YTD-20.34%
Technical Indicators
RSI (14)58.68
50-Day SMA$0.042
200-Day SMA$0.051
Latest News
Biotechnology
Emyria Poised for Operational Boost as TGA Broadens Psych-Therapy Prescriber Access
Emyria is set to accelerate recruitment as TGA broadens Authorised Prescriber roles for psychedelic therapy, boosting Empax network expansion into H2 2026.
Biotechnology
Emyria Launches Empax Global Partnership Platform Targeting International Drug Sponsors
Emyria unveils Empax global partnership platform to link international sponsors with its clinical delivery network; Psyence signs for Phase IIb trial.
Biotechnology
Emyria Introduces First Empax Centre to Victoria with Expanded Medibank Funding Agreement
Emyria expands Medibank funding to Victoria, unlocking Empax TRD/PTSD care at Avive Mornington Peninsula; nationwide rollout underway.
Biotechnology
Emyria Establishes First Victorian Empax Clinic for Psychedelic-Assisted Treatments
Perth-based mental health care specialist Emyria (ASX: EMD) has secured its first Empax clinic in Victoria for the psychedelic-assisted treatment of post-traumatic stress disorder (PTSD) and treatment-resistant depression.